Insitro, an AI-based pharma company, recently raised $143M summing up the venture capital to $243M. The firm will use this fund to hire experienced drug developers and also to fuel its liver-disease drug project. In 2019, it dealt with Gilead for this $1B project, gaining $15M upfront. Insitro focusses on neuroscience and hence uses human cells for neurological disease drug development. Also, it uses fresh training data to train its ML models.